You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 14, 2024

Claims for Patent: 11,261,198


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 11,261,198
Title:Process for preparing substituted polycyclic pyridone derivative and crystal thereof
Abstract: The present invention provides a process for preparing a compound of the formula (II): ##STR00001## wherein R.sup.2 is unsubstituted alkyl, characterized by reacting a compound of the formula (I): ##STR00002## wherein R.sup.1 is hydrogen or a protecting group other than unsubstituted alkyl, with a compound of the formula: R.sup.2--OH, wherein R.sup.2 is as defined above, in the presence of a sodium salt and/or a magnesium salt.
Inventor(s): Shibahara; Setsuya (Amagasaki, JP), Anan; Kosuke (Toyonaka, JP)
Assignee: SHIONOGI & CO., LTD. (Osaka, JP)
Application Number:16/310,897
Patent Claims: 1. A process for preparing a compound of the formula (IV): ##STR00043## or a salt thereof, wherein R.sup.3, R.sup.4, R.sup.5 and R.sup.6 are each independently hydrogen or halogen, provided that one or two of R.sup.3, R.sup.4, R.sup.5 and R.sup.6 is halogen; the process comprising reacting a compound of the formula (II'): ##STR00044## or a salt thereof, with a compound of the formula (III): ##STR00045## or a salt thereof, wherein R.sup.3, R.sup.4, R.sup.5 and R.sup.6 are as defined above.

2. The process according to claim 1, wherein R.sup.3 is hydrogen, R.sup.4 is hydrogen, R.sup.5 is fluorine, and R.sup.6 is fluorine.

3. A process for preparing a compound of the formula (V) or formula (VI): ##STR00046## or a salt thereof, which comprises preparing a compound of the formula (II): ##STR00047## or a salt thereof, wherein R.sup.2 is unsubstituted alkyl; wherein the process of preparing the compound of the formula (II) comprises reacting a compound of the formula (I): ##STR00048## wherein R.sup.1 is hydrogen or a protecting group other than unsubstituted alkyl, with a compound of the formula: R.sup.2--OH, wherein R.sup.2 is as defined above, in the presence of a sodium salt and/or a magnesium salt.

4. A compound of the formula (IV'): ##STR00049## or a salt thereof.

5. A mesylate salt of the compound of formula (IV') according to claim 4.

6. A crystal of the mesylate salt according to claim 5.

7. A crystal of a compound of the formula (V): ##STR00050## or a crystal of a pharmaceutically acceptable salt thereof.

8. The crystal according to claim 6, comprising an X-ray powder diffraction pattern wherein the diffraction angles (2.theta.) of at least two peaks are selected from the group consisting of 7.1.+-.0.2.degree., 9.3.+-.0.2.degree., 12.6.+-.0.2.degree., 14.1.+-.0.2.degree., 17.7.+-.0.2.degree., 18.7.+-.0.2.degree., 19.2.+-.0.2.degree., 22.2.+-.0.2.degree., 25.4.+-.0.2.degree., 27.7.+-.0.2.degree., 28.5.+-.0.2.degree., and 37.8.+-.0.2.degree..

9. The crystal according to claim 6, comprising an X-ray powder diffraction pattern comprising peaks at the diffraction angles (2.theta.) of 7.1.+-.0.2.degree., 9.3.+-.0.2.degree., 12.6.+-.0.2.degree., 14.1.+-.0.2.degree., 17.7.+-.0.2.degree., 18.7.+-.0.2.degree., 19.2.+-.0.2.degree., 22.2.+-.0.2.degree., 25.4.+-.0.2.degree., 27.7.+-.0.2.degree., 28.5.+-.0.2.degree., and 37.8.+-.0.2.degree..

10. The crystal according to claim 6, having a melting point of 219.degree. C..+-.2.degree. C. in differential scanning calorimetry.

11. The crystal according to claim 7, comprising an X-ray powder diffraction pattern wherein the diffraction angles (2.theta.) of at least two peaks are selected from the group consisting of 9.6.+-.0.2.degree., 10.9.+-.0.2.degree., 17.8.+-.0.2.degree., 21.5.+-.0.2.degree., 22.1.+-.0.2.degree., 23.5.+-.0.2.degree., and 24.8.+-.0.2.degree..

12. The crystal according to claim 7, comprising an X-ray powder diffraction pattern comprising peaks at the diffraction angles (2.theta.) of 9.6.+-.0.2.degree., 10.9.+-.0.2.degree., 17.8.+-.0.2.degree., 21.5.+-.0.2.degree., 22.1.+-.0.2.degree., 23.5.+-.0.2.degree., and 24.8.+-.0.2.degree..

13. A process for preparing a compound of the formula (IV'): ##STR00051## or a salt thereof, the process comprising reacting a compound of the formula (II'): ##STR00052## or salt thereof, with a compound of the formula (III): ##STR00053## or a salt thereof, wherein R.sup.3 is hydrogen, R.sup.4 is hydrogen, R.sup.5 is fluorine, and R.sup.6 is fluorine.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.